American Society of Hematology (ASH) 2021
Categorized Hematologic Response To Pegcetacoplan And Correlations With Quality Of Life In Patients With Paroxysmal Nocturnal Hemoglobinuria: Post Hoc Analysis Of Data From Phase 1b, Phase 2a, And Phase 3 Trials
Changes In Hemoglobin Measures Observed In PNH Patients Treated With Both C5 Inhibitors Ravulizumab And Eculizumab: Real-World Evidence From A US-Based EMR Network
Cost Per Responder Analysis For Pegcetacoplan And Eculizumab In The Treatment Of Adults With Paroxysmal Nocturnal Hemoglobinuria
Efficacy And Safety Of Pegcetacoplan Treatment In Complement-Inhibitor Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From The Phase 3 PRINCE Study
Evaluation Of The Long-Term Safety And Efficacy Of Pegcetacoplan Treatment For Paroxysmal Nocturnal Hemoglobinuria Patients: An Extension Study
Post Hoc Analysis Of The Effect Of Pegcetacoplan Treatment On Patients With Paroxysmal Nocturnal Hemoglobinuria And Baseline Hemoglobin Levels Greater Than 10 G/DL
Real-World Ravulizumab Dosing Patterns Among Patients with Paroxysmal Nocturnal Hemoglobinuria in a US Population
The Pharmacokinetics, Pharmacodynamics, And Safety Of Intravenous Pegcetacoplan Treatment In Healthy Subjects